ABSTRACT. Short rib-polydactyly syndrome type III (SRPS3) is a perinatal lethal skeletal disorder with polydactyly and multisystem organ abnormalities. While ultrasound of the fetus can detect skeletal abnormalities characteristic of SRPS3, the syndrome is often difficult to diagnose before birth. As SRPS3 is an autosomal recessive disorder, identification of the gene mutations involved could lead to the development of prenatal genetic testing as an accurate method of diagnosis. In this study, we describe genetic screening approaches to identify potential abnormalities associated with SRPS3. Karyotype analysis, array comparative genomic hybridization (aCGH), and nextgeneration panel sequencing were each performed on a fetus showing signs of the disorder, as well as on the mother and father. Karyotype and aCGH results revealed no abnormalities. However, next-generation panel sequencing identified novel mutations in the DYNC2H1 gene. The fetus was compound heterozygous for both a missense mutation c.8313A > T and a frameshift mutation c.10711_10714delTTTA in the DYNC2H1 gene, which were inherited from the mother and father, respectively. These variants were further confirmed using Sanger sequencing and have not been previously reported. Our study indicates the utility of using next-generation panel sequencing in screening for novel disease-associated mutations.
INTRODUCTION
Short rib-polydactyly syndrome type III (SRPS3) is a perinatal lethal skeletal disorder with polydactyly and multisystem organ abnormalities. It belongs to a group of syndromes called SRPS of which there are five different types: SRPS I [Saldino-Noonan syndrome (MIM 263530) ], SRPS II [Majewski syndrome (MIM 263520) ], SRPS III [Verma-Naumoff syndrome (MIM 263510) ], SRPS IV [Beemer-Langer syndrome (MIM 269860)], and SRPS V (MIM 614091). SRPS3 is an autosomal recessive disease characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas other forms are compatible with life. Recently some studies have found that mutations in the genes WDR34, WDR60, IFT80, NEK1, and DYNC2H1 could cause SRPS3 (Table 1) .
Here we present a case study of a fetus with short limbs identified during ultrasound examination. We describe the application of molecular screening methods to identify genetic abnormalities with a particular focus on genes associated with the development of short limbs.
Tp: terminated preganancy; wg: week of gestation. 
MATERIAL AND METHODS

Case subjects
The case subject was a 31-year-old woman at four months of pregnancy. Upon ultrasound examination, her fetus was observed to have a shortened bilateral long bone and femur, the shaft of the femur was bent, the end of the shaft of the femur was bulky, and the ribs were short and small. The skeletal system of the fetus was abnormal. The woman was previously pregnant with a fetus that exhibited the same ultrasonic detection patterns, so both mother and father (33 years old) were referred to a prenatal diagnosis clinic and chromosomal analysis was recommended. Neither the mother nor father had a history of consanguinity or genetic disease. They did not smoke or drink, and had not been exposed to radiation or chemical insult. Routine blood, urine, liver, and renal function analyses were normal for both, and electrocardiography and chest X-rays showed no abnormalities in the heart and lungs. The pregnancy was later terminated and the aborted fetus was found to have four shortened limbs. Informed consent was obtained from both parents for participation in this study, and both were made aware that their information may be used in future research. Participant information was not anonymized, and all authors had access to identifying information. The study was approved by the No. 202 Hospital of People's Liberation Army (PLA) Ethics Committee.
Karyotyping
Karyotyping was performed on G-banded metaphases obtained from peripheral blood of the parents and cultured using standard procedures. Karyotyping of amniotic fluid was performed at 18 weeks of pregnancy according to standard techniques (Chandler and Yunis, 1978) . Results are described in accordance with the 2013 International System for Human Cytogenetic Nomenclature (ISCN).
Array comparative genomic hybridization analysis
Genomic DNA was extracted from peripheral blood (parents) and amniocytes (fetus) using a DNA extraction kit (Tiangen, China) according to the manufacturer instructions. Array comparative genomic hybridization (aCGH) analysis was performed with oligonucleotidebased custom arrays (Agilent Technologies, Santa Clara, CA, USA) using standard protocols. Briefly, equal amounts of test DNA and normal sex-matched DNA, which is from 100 unrelated health controls, were digested with AluI and RsaI. Next, they were differentially labeled with cyanine-5 and cyanine-3 fluorescent dyes using a SureTag Complete DNA Labeling Kit (Agilent Technologies). Hybridizations were carried out at 65°C for 24 h. After washing, slides were scanned using an Agilent SureScan Microarray Scanner, and the images were extracted and analyzed using Feature Extraction v11.5 and Cytogenomics v2.5 software (Agilent Technologies), respectively.
Next-generation panel sequencing
Targeted sequence capture and next generation sequencing Targeted sequence capture was performed using a protocol developed at the Beijing Genomics Institute (BGI). In brief, 1 mg genomic DNA was fragmented into lengths of 200 bp followed in sequence by end-repair, A-tailing and adaptor ligation, a 4-cycle pre-capture polymerase chain reaction (PCR) amplification, targeted sequence capture, and 15-cycle post-capture PCR. Targeted sequence capture was performed using custom oligonucleotide probe sets (NimbleGen, Roche, Basel, Switzerland) which cover the exons and immediately adjacent intron region of 463 genetic short-limbed genes (Table 2) . Sequencing was performed on a HiSeq 2000 platform (Illumina, San Diego, CA, USA) as paired end 90 bp according to the manufacturer instructions. The targeted regions were covered by a mean depth of over 190-fold, with 99.45% of the targeted region covered by at least one read and 97.71% by at least 20 reads.
Read mapping, variant detection, annotation, and interpretation
Image analyses, error estimation and base calling were performed using the Illumina Pipeline (version 1.3.4) to generate primary sequence data. Low-quality reads and potential adaptor contaminations were removed from the primary data using a local algorithm. The remaining short-reads were mapped to the human genome (hg18) using Burrows-Wheeler Aligner software (http://sourceforge.net/projects/bio-bwa/). Single nucleotide variants (SNVs) were detected using Short Oligonucleotide Analysis Package single nucleotide polymorphism software (http: //soap.genomics.org.cn/) and small insertions and deletions (InDels) were detected using sequence alignment/maps tools Pileup software (http://sourceforge.net/ projects/samtools/). Variants were annotated using a BGI in-house developed annotation pipeline and were interpreted according to the American College of Medical Genetics and Genomics recommended standards (Richards et al., 2008) .
Confirmation by Sanger sequencing
Potential mutations identified by next-generation panel sequencing were further confirmed by PCR and Sanger sequencing in the proband and the unaffected parents. The specific PCR primers were designed using Primer5 software (Premier Biosoft International, Palo Alto, CA). The products were directly sequenced with an ABI PRISM BigDye kit on an ABI 3730 DNA sequencer (Applied Biosystems, Carlsbad, CA). Sequencing results were analyzed using the DNASTAR package (DNASTAR, Madison, WI).The novel identified variants were subsequently verified and screened in 100 unrelated healthy controls with DNA sequencing
RESULTS
Karyotyping of G-banded metaphases showed that the karyotype of both parents and the fetus were normal (data not shown). Array-CGH analysis also did not reveal any abnormalities, with no copy number changes associated with known microdeletion or microduplication syndromes observed (data not shown).
However, using next-generation panel sequencing, more than 800 SNVs and InDels were identified in each of the three subjects across the 463 short-limbed related genes analyzed. After filtering for potential polymorphism variants (> 0.5% in the 1000 Genomes database (http://www.1000genomes.org/home) and > 0.5% in BGI in-house database) and non-functional relevance, there were between 16 and 17 non-synonymous variants and splicing site/coding InDels remaining (Tables 3 and 4) . Two of these mapped to the DYNC2H1 gene and displayed a typical disease gene inheritance pattern. The mother had a heterozygous c.8313A > T missense mutation, the father had a heterozygous c.10711_10714delTTTA frameshift mutation, and the fetus was compound heterozygous for both. These variants were further confirmed using Sanger sequencing (Figure 1 ). SEC23A, MMP2, ESCO2, RIN2, LMX1B, GHR, SLC35D1, EFNB1, DYM, LIFR, GORAB, SH3BP2, FGFR1, TBX15, COMP, CANT1, TFAP2A, RUNX2, TMCO1, CHRNA1, CTSK, FLNB, EVC, FBN1, B3GAT3, EFTUD2, EIF2AK3, SLC26A2, EVC2, CHRNG, CHRND, SMAD4, POC1A, TBX3, WNT7A, ERCC6, ERCC2, FBN1, ADAMTSL2, EXT2, TRPV4, SF3B4, CA2, WDR19, GDF6, FAM123B, TNFRSF11B, TNNI2 PQBP1, SPG20, G6PC3, HYLS1, NBN, RAI1, IGF2, UBR1, OCRL, CHD7, GLA, CD96, LMNA, PHF6, HRAS, IFT140, SRCAP, CTC1, OTX2, ASXL1, FTO, ANKRD11, HSD17B4, MED12, KIF7, DHCR7, CTDP1, MYH8, DDX11, POR, KAT6B, ALDH3A2, TP63, SDHA, ALPL, MLL, WRN, MAP2K1, NSDHL, FAM20C, NSD1, H19, RECQL4, TRIM37, ZEB2, FOXE1, KANSL1, BANF1, BLM, VPS13B, RAB23, TBX1, HPRT1, SLC16A2, SMARCA2, COX4I2, MAP2K2, NOTCH2, CRLF1, WFS1, ZBTB16, ARX, DLX5, MGP, FGFR2, TAZ, PITX2, ACTB, PLOD2, SLC34A1, MBTPS2, TMEM237, TBCE, MKS1, GPC6, RIPK4, FLNA, GJB6, ERCC3, MPV17, ATPAF2, AQP2 94 Neither of these mutations has been previously reported, nor were they observed in the approximately 6000 controls in the 1000 Genomes Project and the BGI in-house database.
DISCUSSION
The aim of this study was to determine whether a four-month-old fetus with short limbs harbored any genetic abnormalities. Given that the karyotype analysis and aCGH levels were normal in both the fetus and the parents, we suspected a single gene defect. Among a panel of 463 genes associated with short limb development, we identified mutations in the DYNC2H1 gene which is associated with SRPS3.
The DYNC2H1 gene is located at chromosome 11q22.3. It encodes a large cytoplasmic dynein protein involved in the structure and function of cilia. Cilia are highly conserved microtubule-based organelles that project from the cell surface into the extracellular environment and play diverse roles in cellular motility, sensory transduction, and signaling. In humans, ciliary dysfunction is associated with a large spectrum of disorders (Bisgrove and Yost, 2006; Eggenschwiler and Anderson, 2007; Tran et al., 2008) , including defects in a variety of proteins necessary for intraflagellar transport as well as in components of the primary cilia, basal body, and centrosome. Many of these phenotypes include polydactyly and some include abnormal skeletogenesis. Mutations in DYNC2H1 have been associated with a heterogeneous spectrum of conditions related to altered primary cilium function that often involve polydactyly, abnormal skeletogenesis, and polycystic kidneys.
To date, there are several reports of DYNC2H1 mutations being associated with SRPS3. Dagoneau et al. (2009) Okamoto et al. (2015) identified compound heterozygosity for mutations c.5682_5683delAA and c.9070C > T in exons 37 and 57, respectively, of the DYNC2H1 gene in a fetus with SRPS3. Mei et al. (2015) identified compound heterozygosity for mutations c.1151C > T and c.4351C > T in exons 8 and 28, respectively, of the DYNC2H1 gene in a fetus with SRPS3. All cases showed similar radiographic findings, such as shortened long bones and a narrow thorax.
In our study, the DYNC2H1 mutations identified have not been previously reported. The c.8313A > T missense mutation results in an arginine to serine substitution at amino acid position 2771. The c.10711_10714delTTTA mutation causes a frameshift that introduces a stop codon at amino acid position 3571, resulting in a truncated protein and possible protein instability. The presence of both of these mutations in the fetus, but only one copy in each of the unaffected parents, follows the pattern of an autosomal recessive disease gene. At the same time, we found the skeletal system of the fetus showed similar characteristic to the reported cases. With the known association between DYNC2H1 mutations and SRPS3, we conclude that these novel mutations are the cause of SRPS3 in the fetus.
We have identified novel mutations in DYNC2H1 that appear to be associated with SRPS3. This was achieved using the innovative approach of next generation sequencing to screen for mutations in a panel of genes potentially associated with the disease under study. Similar application of this new technology to other disorders may enhance our ability to identify disease-associated gene mutations. Furthermore, use of this methodology in prenatal genetic testing could help strengthen our understanding of the genetic causes of birth defects, as well as improve the prospects for early detection.
